The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis

  • Aura Victoria van Asten S
  • Joseph Geradus Peters E
  • Xi Y
  • et al.
47Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.
Get full text

Abstract

© 2016 Bentham Science Publishers. Purpose: To systematically review the value of serum inflammatory markers to diagnose diabetic foot osteomyelitis (DFO). Study selection: Studies to diagnose DFO using biomarkers erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), interleukins (IL-2, IL-6, IL-8) and tumor necrosis factor alfa (TNFα) were retrieved from EMBASE and PubMed with no language restrictions through July 2014. Data extraction: We summarized clinical characteristics of the studies and used bivariate random effects models and summary receiver operating characteristic curves to estimate sensitivity and specificity for each marker. Data synthesis: A total of 8 qualifying studies were included in our meta-analysis. Bivariate pooled sensitivity and specificity of the 6 studies examining ESR were 0.81 (95% CI 0.71-0.88) and 0.90 (95% CI 0.75-0.96) respectively. Due to the paucity of data, models did not converge for the other biomarkers. Conclusions: From the inflammatory markers, ESR appears to be the best laboratory test to identify patients with DFO.

Cite

CITATION STYLE

APA

Aura Victoria van Asten, S., Joseph Geradus Peters, E., Xi, Y., & Alfred Lavery, L. (2016). The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis. Current Diabetes Reviews, 12(4), 396–402. https://doi.org/10.2174/1573399811666150713104401

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free